Your browser doesn't support javascript.
loading
Perturbations of the T-cell receptor repertoire in response to SARS-CoV-2 in immunocompetent and immunocompromised individuals.
Delmonte, Ottavia M; Oguz, Cihan; Dobbs, Kerry; Myint-Hpu, Katherine; Palterer, Boaz; Abers, Michael S; Draper, Deborah; Truong, Meng; Kaplan, Ian M; Gittelman, Rachel M; Zhang, Yu; Rosen, Lindsey B; Snow, Andrew L; Dalgard, Clifton L; Burbelo, Peter D; Imberti, Luisa; Sottini, Alessandra; Quiros-Roldan, Eugenia; Castelli, Francesco; Rossi, Camillo; Brugnoni, Duilio; Biondi, Andrea; Bettini, Laura Rachele; D'Angio, Mariella; Bonfanti, Paolo; Anderson, Megan V; Saracino, Annalisa; Chironna, Maria; Di Stefano, Mariantonietta; Fiore, Jose Ramon; Santantonio, Teresa; Castagnoli, Riccardo; Marseglia, Gian Luigi; Magliocco, Mary; Bosticardo, Marita; Pala, Francesca; Shaw, Elana; Matthews, Helen; Weber, Sarah E; Xirasagar, Sandhya; Barnett, Jason; Oler, Andrew J; Dimitrova, Dimana; Bergerson, Jenna R E; McDermott, David H; Rao, V Koneti; Murphy, Philip M; Holland, Steven M; Lisco, Andrea; Su, Helen C.
Affiliation
  • Delmonte OM; Laboratory of Clinical Immunology and Microbiology National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md. Electronic address: ottavia.delmonte@nih.gov.
  • Oguz C; Integrated Data Sciences Section, Research Technology Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
  • Dobbs K; Laboratory of Clinical Immunology and Microbiology National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
  • Myint-Hpu K; Laboratory of Clinical Immunology and Microbiology National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
  • Palterer B; Laboratory of Clinical Immunology and Microbiology National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
  • Abers MS; Laboratory of Clinical Immunology and Microbiology National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
  • Draper D; Laboratory of Clinical Immunology and Microbiology National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
  • Truong M; Laboratory of Clinical Immunology and Microbiology National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
  • Kaplan IM; Adaptive Biotechnologies, Seattle, Wash.
  • Gittelman RM; Adaptive Biotechnologies, Seattle, Wash.
  • Zhang Y; Laboratory of Clinical Immunology and Microbiology National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
  • Rosen LB; Laboratory of Clinical Immunology and Microbiology National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
  • Snow AL; Laboratory of Clinical Immunology and Microbiology National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md; Department of Pharmacology & Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, Md.
  • Dalgard CL; Department of Anatomy, Physiology & Genetics, Uniformed Services University of the Health Sciences, Bethesda, Md; The American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, Md.
  • Burbelo PD; Adeno-Associated Virus Biology Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Md.
  • Imberti L; Section of Microbiology, University of Brescia, ASST Spedali Civili, Brescia, Italy.
  • Sottini A; Section of Microbiology, University of Brescia, ASST Spedali Civili, Brescia, Italy.
  • Quiros-Roldan E; Department of Infectious and Tropical Diseases, University of Brescia, ASST Spedali Civili, Brescia, Italy.
  • Castelli F; Department of Infectious and Tropical Diseases, University of Brescia, ASST Spedali Civili, Brescia, Italy.
  • Rossi C; Direzione Sanitaria, ASST Spedali Civili, Brescia, Italy.
  • Brugnoni D; Laboratorio Analisi Chimico-Cliniche, ASST Spedali Civili, Brescia, Italy.
  • Biondi A; Pediatric Department and Centro Tettamanti-European Reference Network on Paediatric Cancer, European Reference Network on Haematological Diseases, and European Reference Network on Hereditary Metabolic Disorders, University of Milano-Bicocca-Fondazione MBBM, Monza, Italy.
  • Bettini LR; Pediatric Department and Centro Tettamanti-European Reference Network on Paediatric Cancer, European Reference Network on Haematological Diseases, and European Reference Network on Hereditary Metabolic Disorders, University of Milano-Bicocca-Fondazione MBBM, Monza, Italy.
  • D'Angio M; Pediatric Department and Centro Tettamanti-European Reference Network on Paediatric Cancer, European Reference Network on Haematological Diseases, and European Reference Network on Hereditary Metabolic Disorders, University of Milano-Bicocca-Fondazione MBBM, Monza, Italy.
  • Bonfanti P; Department of Infectious Diseases, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy.
  • Anderson MV; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
  • Saracino A; Clinic of Infectious Diseases, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, University of Bari, Bari, Italy.
  • Chironna M; Hygiene Section, Department of Interdisciplinary Medicine, University of Bari Aldo Moro, Bari, Italy.
  • Di Stefano M; Department of Medical and Surgical Sciences, Section of Infectious Diseases, University of Foggia, Foggia, Italy.
  • Fiore JR; Department of Medical and Surgical Sciences, Section of Infectious Diseases, University of Foggia, Foggia, Italy.
  • Santantonio T; Department of Medical and Surgical Sciences, Section of Infectious Diseases, University of Foggia, Foggia, Italy.
  • Castagnoli R; Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy; Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Marseglia GL; Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy; Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
  • Magliocco M; Molecular Development of the Immune System Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
  • Bosticardo M; Laboratory of Clinical Immunology and Microbiology National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
  • Pala F; Laboratory of Clinical Immunology and Microbiology National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
  • Shaw E; Laboratory of Clinical Immunology and Microbiology National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
  • Matthews H; Molecular Development of the Immune System Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
  • Weber SE; Molecular Development of the Immune System Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
  • Xirasagar S; Bioinformatics and Computational Biosciences Branch, Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
  • Barnett J; Bioinformatics and Computational Biosciences Branch, Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
  • Oler AJ; Bioinformatics and Computational Biosciences Branch, Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
  • Dimitrova D; Center for Immuno-Oncology, National Cancer Institute, National Institutes of Health, Bethesda, Md.
  • Bergerson JRE; Laboratory of Clinical Immunology and Microbiology National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
  • McDermott DH; Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
  • Rao VK; Laboratory of Clinical Immunology and Microbiology National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
  • Murphy PM; Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
  • Holland SM; Laboratory of Clinical Immunology and Microbiology National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
  • Lisco A; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
  • Su HC; Laboratory of Clinical Immunology and Microbiology National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
J Allergy Clin Immunol ; 153(6): 1655-1667, 2024 Jun.
Article in En | MEDLINE | ID: mdl-38154666
ABSTRACT

BACKGROUND:

Functional T-cell responses are essential for virus clearance and long-term protection after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, whereas certain clinical factors, such as older age and immunocompromise, are associated with worse outcome.

OBJECTIVE:

We sought to study the breadth and magnitude of T-cell responses in patients with coronavirus disease 2019 (COVID-19) and in individuals with inborn errors of immunity (IEIs) who had received COVID-19 mRNA vaccine.

METHODS:

Using high-throughput sequencing and bioinformatics tools to characterize the T-cell receptor ß repertoire signatures in 540 individuals after SARS-CoV-2 infection, 31 IEI recipients of COVID-19 mRNA vaccine, and healthy controls, we quantified HLA class I- and class II-restricted SARS-CoV-2-specific responses and also identified several HLA allele-clonotype motif associations in patients with COVID-19, including a subcohort of anti-type 1 interferon (IFN-1)-positive patients.

RESULTS:

Our analysis revealed that elderly patients with COVID-19 with critical disease manifested lower SARS-CoV-2 T-cell clonotype diversity as well as T-cell responses with reduced magnitude, whereas the SARS-CoV-2-specific clonotypes targeted a broad range of HLA class I- and class II-restricted epitopes across the viral proteome. The presence of anti-IFN-I antibodies was associated with certain HLA alleles. Finally, COVID-19 mRNA immunization induced an increase in the breadth of SARS-CoV-2-specific clonotypes in patients with IEIs, including those who had failed to seroconvert.

CONCLUSIONS:

Elderly individuals have impaired capacity to develop broad and sustained T-cell responses after SARS-CoV-2 infection. Genetic factors may play a role in the production of anti-IFN-1 antibodies. COVID-19 mRNA vaccines are effective in inducing T-cell responses in patients with IEIs.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Immunocompromised Host / SARS-CoV-2 / COVID-19 Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Allergy Clin Immunol Year: 2024 Type: Article

Full text: 1 Database: MEDLINE Main subject: Immunocompromised Host / SARS-CoV-2 / COVID-19 Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Allergy Clin Immunol Year: 2024 Type: Article